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Emerging evidence suggests that unregulated Toll-like receptors (TLRs) signaling promotes tumor survival 33 
signals, thus favoring tumor progression. Here, the mechanism underlying TLR4 overexpression in papillary 34 
thyroid carcinomas (PTCs) mainly harboring the BRAFV600E mutation was studied. TLR4 was overexpressed in 35 
PTCs compared to non-neoplastic thyroid tissue. Moreover, paired clinical specimens of primary PTC and its 36 
lymph node metastasis showed a significant upregulation of TLR4 levels in the metastatic tissues. In 37 
agreement, conditional BRAFV600E expression in normal rat thyroid cells and mouse thyroid tissue 38 
upregulated TLR4 expression levels. Furthermore, functional TLR4 expression was demonstrated in PTC 39 
cells by increased NF-κB transcriptional activity in response to the exogenous TLR4-agonist 40 
lipopolysaccharide (LPS). Of note, The Cancer Genome Atlas (TCGA) data analysis revealed that BRAFV600E-41 
positive tumors with high TLR4 expression were associated with shorter disease-free survival. 42 
Transcriptomic data analysis indicated a positive correlation between TLR4 expression levels and 43 
MAPK/ERK signaling activation. Consistently, chemical blockade of MAPK/ERK signaling abrogated 44 
BRAFV600E-induced TLR4 expression. A detailed study of the TLR4 promoter revealed a critical MAPK/ERK-45 
sensitive Ets binding-site involved in BRAFV600E responsiveness. Subsequent investigation revealed that the 46 
Ets-binding factor ETS1 is critical for BRAFV600E-induced MAPK/ERK signaling-dependent TLR4 gene 47 
expression. Together, these data indicate that functional TLR4 overexpression in PTCs is a consequence of 48 
thyroid tumor-oncogenic driver dysregulation of MAPK/ERK/ETS1 signaling. 49 
IMPLICATIONS: Considering the participation of aberrant NF-κB signaling activation in the promotion of 50 
thyroid tumor growth and the association of high TLR4 expression with more aggressive tumors, this study 51 
suggests a pro-oncogenic potential of TLR4 downstream signaling in thyroid tumorigenesis. 52 
KEYWORDS: Papillary thyroid carcinoma, BRAFV600E, Toll-like receptor 4, MAPK/ERK signaling pathway, ETS-53 
domain transcription factor family.  54 
on March 11, 2018. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 




The emerging role of Toll-like receptors (TLRs) in the maintenance of tissue homeostasis as critical 56 
regulators of inflammatory processes and tissue regeneration response under physiological conditions has 57 
led to the identification of aberrant functions of these receptors in different diseases, including 58 
inflammatory and infectious disorders, autoimmunity and cancer (1). Particularly, unregulated TLR signaling 59 
has been described in several neoplastic processes associated with exacerbated production of pro-60 
inflammatory cytokines involved in tumor progression (1,2). Indeed, TLR signaling-deficient mice are 61 
resistant to tumor development in different experimental models (3,4). Likewise, transgenic mice 62 
overexpressing constitutively active TLR4 under the intestine-specific villin promoter are highly susceptible 63 
to colitis-associated cancer (5). The close link between dysregulated TLRs function and cancer progression 64 
has set the molecular basis for the development of potential therapeutics targeting TLRs or TLRs-triggered 65 
intracellular signal pathways (6).  66 
Chronic activation of the immune system and tissue response might generate an inadequate negative 67 
regulation of TLRs signal pathways leading to an excessive pro-inflammatory microenvironment that 68 
facilitates the promotion of neoplastic processes (7). Different TLRs polymorphisms have been associated 69 
with increased susceptibility or severity of infections (8). Of note, the polymorphism rs4986790 in TLR4 70 
gene was identified as risk factor for the development of gastric cancer in Helicobacter pylori-infected 71 
patients (9).  72 
Functional TLRs expression in tumor cells has been linked to tumor survival and progression, evasion of 73 
immune system and resistance to apoptosis. TLR4 engagement in lung cancer cells induces the expression 74 
of immunosuppressive and pro-angiogenic cytokines (10). Further studies in prostate cancer cells showed 75 
that TLR4 activation promotes the secretion of pro-angiogenic cytokines in response to NF-κB signaling (11). 76 
However, discrepancies regarding tumor cell survival in response to TLR4 activation in different cell models 77 
have been observed. Particularly, TLR4 signaling improves survival in ovarian cancer cells (12) and promotes 78 
the invasive ability of colon cancer cells (13). Conversely, studies in pituitary tumors showed that TLR4 79 
activation inhibited tumor growth (14). 80 
In the thyroid tissue, functional TLR3 expression was reported in normal thyrocytes. McCall et al. (15) 81 
demonstrated high constitutive TLR3 signaling in papillary thyroid carcinomas (PTCs) compared to normal 82 
thyroid tissue and follicular thyroid carcinomas (FTCs). Moreover, phenylmethimazole—a small molecule 83 
that decreases TLR3 expression and signaling—inhibited PTC cells growth and migration (15). In addition, 84 
we demonstrated functional TLR4 expression in normal murine thyrocytes (16). Using the exogenous TLR4-85 
agonist lipopolysaccharide (LPS), we demonstrated that NF-κB signaling plays a central role in the 86 
regulation of TLR4-induced thyroid differentiation markers gene expression (17,18). Interestingly, Hagström 87 
et al. (19) reported a significant correlation between high TLR4 protein levels and metastatic potential in 88 
FTCs. Moreover, Dang et al. (20) demonstrated that TLR4 is abundantly expressed in PTCs and stimulation 89 
of the PTC cell line W3 with the endogenous TLR4-agonist low molecular weight hyaluronic acid promotes 90 
cell proliferation and migration. 91 
Here, we investigated the molecular events downstream thyroid cancer-driving oncogenes involved in the 92 
upregulation of TLR4 gene expression in differentiated thyroid carcinomas. As previously described, we 93 
show that TLR4 is aberrantly overexpressed in PTCs and FTCs. Moreover, TLR4 expression is functional as its 94 
exogenous agonist LPS increased NF-κB transcriptional activity in PTC cell models. Consistent with 95 
transcriptomic data of PTC showing a significant correlation between TLR4 mRNA expression levels and ERK 96 
activation score, chemical blockage of MAPK/ERK signaling abrogated BRAFV600E-induced TLR4 expression. 97 
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MAPK/ERK signaling-dependent BRAFV600E-induced TLR4 gene expression relies on a distal Ets binding-site 98 
identified in the TLR4 promoter. Moreover, we show that the Ets-binding factor ETS1 is critical for 99 
BRAFV600E-induced MAPK/ERK signaling-mediated TLR4 gene expression in thyroid carcinomas. In sum, high 100 
TLR4 levels in PTC cells is the consequence of dysregulated MAPK/ERK signaling as result of thyroid tumors-101 
drivers such as BRAFV600E. Altogether, our evidence suggests a pro-oncogenic potential of TLR4 signaling in 102 
thyroid tumorigenesis, further considering the oncogenic potential of NF-κB signaling in the promotion of 103 
thyroid cancer (21).  104 
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MATERIAL AND METHODS 105 
Immunohistochemistry. TLR4 and ETS1 expression in clinical thyroid samples was studied using low and 106 
high-density human thyroid tissue arrays (US Biomax - Rockville, MD, USA). Endogenous peroxidase activity 107 
was blocked by treatment with H2O2 in methanol for 15 min. Thyroid sections were then incubated for 30 108 
min in 5% normal rabbit serum to block non-specific binding, followed by overnight incubation with 1 µg/ml 109 
goat polyclonal anti-TLR4 antibody (sc-16240, Santa Cruz Biotechnology - Santa Cruz, CA, USA), 5 µg/ml 110 
mouse monoclonal anti-TLR4 antibody (ab-22048, Abcam - Cambridge, MA, USA) or 3.3 μg/ml rabbit 111 
polyclonal anti-ETS1 antibody (sc-350, Santa Cruz Biotechnology) at 4 °C in a humidified chamber. For 112 
negative controls, the primary antibody was replaced by the corresponding purified non-reactive IgG in a 113 
separate slide containing paraffin-embedded thyroid carcinoma tissue samples. Afterward, thyroid sections 114 
were incubated with biotinylated secondary antibody (Santa Cruz Biotechnology) and ABC complex (Vector 115 
Laboratories - Burlingame, CA, USA). 3,3'-Diaminobenzidine (DAB) (Sigma-Aldrich, St Louis, MO, USA) was 116 
used as the chromogenic substrate for 10 min at RT, and the sections were rinsed in running water and 117 
counterstained with Harris hematoxylin. Digital images were captured at 400x magnification using a Nikon 118 
Eclipse TE2000-U light microscope (Nikon Instruments, Japan). Quantification of TLR4 and ETS-1 protein 119 
levels was performed by assessing DAB staining intensity relative to the number of cells in the histological 120 
sections in order to correct differences in tissue architecture. DAB staining intensity and the number of 121 
nuclei seen in one randomly selected area of each tissue section were quantified using ImageJ software 122 
(National Institute of Health - Bethesda, MD, USA). 123 
Plasmids. The expression vectors encoding human BRAFV600E and dominant-negative human Δ152–296 124 
MyD88 were as reported (22,23). pCMV-mFlagEts1 (plasmid #86099) was from Addgene (Cambridge, MA, 125 
USA). The NF-κB reporter vector containing five κB consensus sites linked to the luciferase coding sequence 126 
(5x κB-Luc) and the expression vector encoding dominant-negative mouse Δ670-835 TLR4 were from 127 
Clontech (Palo Alto, CA, USA) and InvivoGen (San Diego, CA, USA), respectively. Mouse TLR4 promoter 128 
constructs +52/+223, -104/+223, -336/+223 and -608/+223 were as reported (24). Disruption of the distal 129 
Ets binding-site in the mouse TLR4 promoter was performed by PCR with the oligonucleotide 5’-130 
TGGGTTTTAATCTCTAGCATTGTGAGAAAATATGTAGTTCTAGTCTGAAACATCCA carrying the desire mutation 131 
(underlined) using KOD Hot Start DNA polymerase (EMD Millipore - Temecula, CA, USA) as described (25). 132 
The artificial ETS reporter 3x Etsd-Luc contains the luciferase gene under the control of a promoter 133 
containing three copies in tandem of the flanking region of the distal Ets binding-site 134 
(AAAATATGTTCCTCTAGTCTGA) of mouse TLR4 promoter upstream the adenovirus E1B core promoter. The 135 
normalization reporter pCMV-β-galactosidase was obtained from Promega (Madison, WI, USA). All 136 
constructs were sequenced to verify nucleotide sequence (Instituto Nacional de Tecnología Agropecuaria, 137 
Buenos Aires, Argentina). 138 
Cell culture. The Fischer rat thyroid cell line PCCl3 was kindly provided by Dr. Roberto Di Lauro (Università 139 
degli Studi di Napoli Federico II, Naples, Italy). PCCl3 thyroid cells engineered to obtain doxycycline-140 
inducible expression of the oncogenes BRAFV600E (PC/BRAFV600E), RET/PTC3 (PC/PTC3) and HRasG12V 141 
(PC/HRasG12V) were generously provided by Dr. James Fagin (Memorial Sloan-Kettering Cancer Center, New 142 
York, USA). PCCl3 and PCCl3-derived cells were cultured in DMEM/Ham F-12 medium supplemented with 143 
5% calf serum (Thermo-Fisher Scientific - Waltham, MA, USA), 1 mIU/ml bovine TSH (National Hormone and 144 
Peptide Program, Harbor-UCLA Medical Center - Torrance, CA, USA), 10 μg/ml bovine insulin and 5 μg/ml 145 
bovine transferrin (Sigma-Aldrich) and treated with 1 μg/ml of doxycycline (Sigma-Aldrich) to induce 146 
oncogene expression (26). Non-tumoral human thyroid cell line Nthy-ori 3-1 was obtained from the 147 
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European Collection of Authenticated Cell Cultures (Salisbury, United Kingdom) and human PTC-derived cell 148 
line BCPAP—harboring the BRAFV600E mutation—was provided by Dr. Massimo Santoro (Università degli 149 
Studi di Napoli Federico II, Naples, Italy). Human thyroid cells were cultured in DMEM medium 150 
supplemented with 10% fetal bovine serum (PAA Laboratories, Pasching, Austria). Human cell lines were 151 
authenticated using short tandem repeat genotyping using PowerPlex Fusion System (Promega) at Centro 152 
de Excelencia en Procesos y Productos de Córdoba (Córdoba, Argentina). Cells were also regularly tested 153 
for mycoplasma contamination using in-house PCR assays. Chemical inhibitors were obtained from the 154 
following suppliers and used at the indicated concentrations: PLX4032 (Selleck Chemicals - Houston, TX, 155 
USA), BAY 11-7082 (Sigma-Aldrich) and U0126 (Cell Signaling Technology - Danvers, MA, USA). The 156 
endotoxin lipopolysaccharide from E. coli 055:B5 was purchased from Sigma-Aldrich. 157 
Transgenic Mice. FVB/N mice carrying thyroid-specific human BRAFV600E gene expression under the 158 
regulation of the bovine thyroglobulin promoter (Tg-BRAFV600E) were provided by Dr. James Fagin (27). All 159 
procedures were approved by the Institute of Biomedical Sciences, University of São Paulo (São Paulo, 160 
Brazil) Ethical Committee for Animal Research. 161 
RNA isolation and Real-time PCR. Total RNA purification, cDNA synthesis, and quantitative PCR (qPCR) 162 
were performed as described (28). Gene specific primer sets were as follow: mouse/rat TLR4 (180 bp) 5’-163 
CCAAGAACCTRGAYCTGAGC (forward) and 5’-TCTTGATAGGGTTTCCTGTC (reverse), human TLR4 (180 bp) 5’-164 
CCAAGAACCTGGACCTGAGC (forward) and 5’-TCTGGATGGGGTTTCCTGTC (reverse), rat IL-6 (109 bp) 5’-165 
GACAAAGCCAGAGTCATTCAGAGC (forward) and 5’-GAGCATTGGAAGTTGGGGTAGG (reverse), rat iNOS (137 166 
bp) 5’-CTTCCGAAGTTTCTGGCAGCAG (forward) and 5’-GGACCATCTCCTGCATTTCTTCC (reverse), human IL-6 167 
(290 bp) 5’-GGATGCTTCCAATCTGGATTCAATGAG (forward) and 5’-CGCAGAATGAGATGAGTTGTCATGTCC 168 
(reverse), human iNOS (104 bp) 5’- TGGCAGCATCAGAGGGGACC (forward) and 5’-169 
GCAGGACAGGGGACCACATCGAA (reverse), human β-actin (109 bp) 5’-ACTCTTCCAGCCTTCCTTCC (forward) 170 
and 5’- GTTGGCGTACAGGTCTTTGC (reverse), rat β-actin (223 bp) 5’- CTACAATGAGCTGCGTGTGG (forward) 171 
and 5’- GGGCACAGTGTGGGTGAC (reverse), mouse β-actin (157 bp) 5’- CAGCTTCTTTGCAGCTCCTT (forward) 172 
and 5’- CACGATGGAGGGGAATACAG (reverse). Relative changes in gene expression were calculated using 173 
the 2-ΔΔCt method normalized against the housekeeping gene β-actin. For each pair of primers a dissociation 174 
plot resulted in a single peak, indicating that only one cDNA species was amplified. The amplification 175 
efficiency for each pair of primers was calculated using standard curves generated by serial dilutions of 176 
cDNA generated from PCCl3 or BCPAP cells. All amplification efficiencies ranged between 97-105% in 177 
different assays. 178 
Immunoblotting. SDS-PAGE, electrotransference to nitrocellulose membranes, and immunoblotting were 179 
as described (29). Membranes were incubated with 0.2 μg/ml mouse monoclonal anti-TLR4 (ab-22048, 180 
Abcam), 0.2 μg/ml rabbit polyclonal anti-BRAF (sc-166, Santa Cruz Biotechnology), 0.2 μg/ml mouse 181 
monoclonal anti-p-ERK (sc-7383, Santa Cruz Biotechnology), 0.2 μg/ml rabbit polyclonal anti-ERK (sc-94, 182 
Santa Cruz Biotechnology), 0.2 μg/ml rabbit polyclonal anti-ETS1 (sc-350, Santa Cruz Biotechnology), 0.2 183 
μg/ml rabbit polyclonal anti-PARP-1 (sc-7150, Santa Cruz Biotechnology), 0.4 μg/ml mouse monoclonal 184 
anti-α-Tubulin (T6074, Sigma-Aldrich) antibodies. After washing, membranes were further incubated with 185 
IRDye 680 RD or IRDye 800 CW-linked secondary anti-rabbit and anti-mouse antibodies (LI-COR 186 
Biotechnology - Lincoln, NE, USA), protected from light. Membranes were visualized and quantified by 187 
Odyssey Infrared Imaging System (LI-COR Biotechnology). Equal loading was assessed by stripping and 188 
reprobing the same blot with 0.1 μg/ml rabbit polyclonal anti-GAPDH (sc-25778, Santa Cruz Biotechnology). 189 
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Immunofluorescence. Cells seeded onto glass coverslips were fixed in 2% paraformaldehyde (30). Cells 190 
were immunostained with 10 μg/ml mouse monoclonal anti-TLR4 (ab-22048, Abcam) or 4 μg/ml rabbit 191 
polyclonal anti-ETS1 (sc-350, Santa Cruz Biotechnology) in PBS containing 0.2% BSA. For analysis under 192 
permeabilized conditions an additional 0.1% Triton was added. Secondary staining proceeded with 50 nM 193 
anti-mouse Alexa-594 antibody (Thermo-Fisher Scientific). Nuclear DNA was stained with 4′,6-diamidino-2-194 
phenylindole (DAPI). Coverslips were mounted with FluorSave Reagent (EMD Millipore) and images were 195 
acquired on a Leica DMi8 epifluorescence microscope (Leica Microsystems - Buffalo Grove, IL, USA). The 196 
number of nuclei and the intensity of TLR4 or ETS1 immunostaining were analyzed using ImageJ software. 197 
Transient transfection and reporter gene assay. Cells were transiently co-transfected with 0.64 μg/well of 198 
luciferase reporter vectors or 0.21 μg/well of luciferase reporter vectors plus 0.42 μg/well of expression 199 
vectors and 0.16 μg/well of the normalization reporter β-galactosidase in 24-well plates using 200 
Lipofectamine 2000 (Thermo-Fisher Scientific) (29). The luciferase activity was measured using a Luciferase 201 
Assay System (Promega) according to the manufacturer's instructions and normalized relative to that of β-202 
galactosidase. 203 
Small interference RNA. Negative control siRNA pool (D-001206-13) and rat siRNA specific for ETS1 (sc-204 
156062) were from Dharmacon (Lafayette, CO, USA) and Santa Cruz Biotechnology, respectively. 205 
PC/BRAFV600E cells were seeded at a density of 5x105 cells/well onto 6-well plates and transfected with 10 206 
nM of each siRNA pool using Lipofectamine RNAiMAX reagent (Thermo-Fisher Scientific) according to the 207 
manufacturer’s protocol. ETS1 protein expression was monitored by immunoblotting 48 h after 208 
transfection. 209 
Chromatin Immunoprecipitation (ChIP). Cells were crosslinked in culture media containing 1% 210 
formaldehyde and nuclei were purified and lysed in 50 mM Tris-HCl (pH 8), 10 mM EDTA and 1% sodium 211 
dodecyl sulfate (31). Genomic DNA was broken by sonication and 10-fold diluted in IP Dilution Buffer [50 212 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100 and 0.5% Nonidet P-40]. 213 
Immunoprecipitation was performed with 2 μg non-specific mouse IgG or rabbit polyclonal anti-ETS1 214 
antibody (sc-350, Santa Cruz Biotechnology) (32). Immune complexes were purified with Protein A/G PLUS-215 
Agarose (Santa Cruz Biotechnology) pre-blocked with sonicated salmon sperm DNA (Sigma-Aldrich). 216 
Immunoprecipitates were washed four times with IP Dilution Buffer containing 0.1% SDS; twice with High 217 
Salt IP Wash Buffer [50 mM Tris-HCl (pH 7.5), 500 mM NaCl, 5 mM EDTA, 0.1% SDS and 1% Triton X-100], 218 
and once with TE [10 mM Tris-HCl (pH 8), 1 mM EDTA]. DNA was purified using Chelex-100 (Bio-Rad – 219 
Hercules, CA, USA). Immunoprecipitated DNA was quantified by qPCR using the primer set 5’-220 
GAGAGAGGTCTATTGCCCCATG (forward) and 5’-AGCGTTTGCTGACCAGCTTC (reverse) as described. Relative 221 
fold of increase were calculated according to the equation: 2-[(Ct.input - Ct.target) – (Ct.input - Ct.mock)]. 222 
Statistical analysis. Results are reported as the mean ± SEM from at least three independent experiments. 223 
Multiple group analysis was conducted by one-way ANOVA with Newman-Keuls multiple comparisons post-224 
test. Comparisons between two groups were performed using unpaired Student’s t test or nonparametric 225 
Mann-Whitney test. Immunohistochemistry quantifications were analyzed by the nonparametric Kruskal-226 
Wallis test with Dunn’s multiple comparison post hoc tests. Correlation and disease-free survival analysis 227 
using molecular data derived from The Cancer Genome Atlas were analyzed using Spearman’s correlation 228 
coefficient and Mantel-Cox test, respectively. Statistical analyses were performed using GraphPad Prism 229 
(GraphPad Software - La Jolla, CA, USA). Differences were considered statistically significant at P < 0.05. 230 
  231 
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TLR4 is overexpressed in differentiated thyroid carcinomas. We studied TLR4 expression in normal (n=13) 233 
and malignant thyroid sections, including PTC (n=50) and FTC (n=32) by immunohistochemistry. In 234 
agreement with previous observations (16,19,20), TLR4 expression was detected on normal thyrocytes (Fig. 235 
1A). Interestingly, TLR4 protein levels were significantly higher in differentiated—follicular and papillary—236 
thyroid carcinomas compared to normal thyroid tissue (Fig. 1A), although no statistical differences were 237 
evidenced between papillary and follicular thyroid tumors (Fig. 1A). Moreover, similar changes in TLR4 238 
protein expression were evidenced in independent assays using a different anti-TLR4 antibody (Fig. S1). Of 239 
note, comparison of TLR4 expression levels between matched-samples of tumor adjacent normal thyroid 240 
tissue and PTCs (n=4) showed a significant upregulation of TLR4 levels in the neoplastic tissue (Fig. 1B). No 241 
significant correlation was evidenced between TLR4 protein immunostaining and tumor, node and 242 
metastasis (TNM) staging in PTCs or FTCs (Fig. S2). Significantly, TLR4 protein expression was also detected 243 
in lymph node metastasis derived from PTCs (Fig. 1C). Comparison of TLR4 expression levels between 244 
matched-samples of primary PTCs and its lymph node metastasis (n=8) showed a significant upregulation of 245 
TLR4 levels in the metastatic tissue (Fig. 1C).  246 
Thereafter, we used molecular data derived from The Cancer Genome Atlas (TCGA) study of PTC (33) to 247 
perform combined analysis of TLR4 mRNA expression as a function of the most frequent driver oncogenes 248 
identified in PTCs, including point mutations and gene fusions (33). Although TLR4 mRNA levels were found 249 
unaltered in PTCs harboring different tumor driving oncogenes, we noticed a highly heterogeneous TLR4 250 
expression among PTCs harboring the same oncogene (Fig. 1D). However, a significant positive correlation 251 
was evidenced between TLR4 mRNA expression levels and ERK activation score (rs=0.1280, P=0.0189), an 252 
evaluation of the activation status of MAPK/ERK signaling (33), suggesting that oncogene-stimulated 253 
MAPK/ERK signaling is an important event driving TLR4 gene expression in PTCs (Fig. 1E). In agreement, the 254 
Gene Expression Omnibus (GEO) dataset GSE33630 analysis also showed a significant positive correlation 255 
between TLR4 mRNA expression levels and ERK activation score in PTC (Fig. S3). 256 
Thereafter, we focused our analysis on PTCs harboring the oncogene BRAFV600E as this mutation has been 257 
reported to occur in 30-80% of PTCs (34). We evidenced a significant positive correlation between TLR4 258 
mRNA expression and the thyroid differentiation score (rs=0.1436, P=0.0302), an evaluation of the 259 
dedifferentiation status of the tumor (33), supporting that TLR4 gene expression is higher in more 260 
differentiated PTCs (Fig. 1F). Moreover, we observed a non-significant positive association between TLR4 261 
mRNA expression and MACIS score (rs=0.1039, P=0.1548), an outcome predictor in patients with PTC (Fig. 262 
1G). The modest association may be due in part to the characteristics of the patients, as most of them fall 263 
into the low-risk category (MACIS score <6). Thereafter, patient samples harboring the oncogene BRAFV600E 264 
(wild-type TERT status) were divided into the high or low cohort based on the median expression of TLR4 265 
mRNA levels within the group. Interestingly, patients whose tumors showed high TLR4 expression, based on 266 
TLR4 expression above the median, had a lower median disease-free survival than those who showed TLR4 267 
expression below the median (TLR4high=26.63 months vs. TLR4low=31.24 months, P=0.0071) (Fig. 1H). 268 
Together, these data suggest that TLR4 mRNA expression constitutes a potential marker of PTC 269 
aggressiveness. 270 
 271 
PTC-driving oncogenes induce TLR4 expression. In order to study oncogene-driving TLR4 gene expression, 272 
we analyzed TLR4 mRNA expression in PCCl3 thyroid cell conditionally expressing the oncogenes BRAFV600E, 273 
HRASG12V, or RET/PTC3 in response to doxycycline. In PCCl3 cells, doxycycline treatment did not up-regulate 274 
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TLR4 mRNA expression. Conversely, in PC/BRAFV600E, PC/HRasG12V and PC/PTC3 cells doxycycline-induced 275 
oncogene expression was associated with a significant increase of TLR4 mRNA expression (Fig. 2A). 276 
Additionally, we assessed TLR4 protein expression in PC/BRAFV600E cells in response to doxycycline. 277 
BRAFV600E expression significantly increased TLR4 protein levels in PC/BRAFV600E cells (Fig. 2B). Furthermore, 278 
transient transfection of BRAFV600E into non-tumoral Nthy-ori 3-1 thyroid cells significantly increased TLR4 279 
protein expression levels compared to those of empty vector-transfected cells (Fig. 2C). Analysis of ERK 280 
phosphorylation was used to assess BRAFV600E oncogenic activity. Complementary, immunofluorescence 281 
performed under non-permeabilized conditions showed increased TLR4 protein levels at the plasma 282 
membrane in response to BRAFV600E expression (Fig. 2D). Similar observations were done in PCCl3 cells 283 
conditionally expressing the oncogenes HRasG12V and RET/PTC3 (Fig. S4). 284 
In order to further confirm our findings, TLR4 mRNA expression was studied in five-week old transgenic 285 
mice conditionally expressing the oncogene BRAFV600E in the thyroid follicular cell (27). The thyroid tumors 286 
of transgenic mice showed significantly higher TLR4 mRNA expression levels compared to that of non-287 
transgenic littermates controls (Fig. 2E). In addition, the expression of TLR4 protein levels in paraffin-288 
embedded normal and malignant mice thyroid tissues was assessed by immunohistochemistry. 289 
Accordingly, TLR4 immunostaining was significantly increased in the thyroid tumor tissue of BRAFV600E-290 
expresing mice compared to littermates controls (Fig. 2F). 291 
 292 
Functional TLR4 protein expression in cell models of PTC. All TLRs signaling pathways culminate in 293 
activation of the transcription factor NF-κB (35). Therefore, the functionality of TLR4 overexpression in 294 
thyroid carcinomas was assessed by analyzing NF-κB signaling activation in response to the TLR4 agonist 295 
LPS. Consistently with previous observations indicating the activation of NF-κB signaling in response to 296 
BRAFV600E expression (34), doxycycline-treated PC/BRAFV600E cells showed a significant induction of the NF-297 
κB reporter 5x κB-Luc (Fig. 3A). Interestingly, LPS treatment induced a significant upregulation of NF-κB 298 
transcriptional activity in doxycycline-treated PC/BRAFV600E cells (Fig. 3A). The NF-κB inhibitor BAY 11-7082 299 
was used to investigate the specific activation of NF-κB pathway (Fig. 3A). Moreover, consistently with the 300 
activation of NF-κB signaling in response to TLR4 activation, we observed a significant BAY 11-7082-301 
sensitive increase in the mRNA expression of the well-known TLR4-induced NF-κB targets interleukin-6 (IL-302 
6) and inducible nitric oxide synthase (iNOS) in response to LPS stimulation in doxycycline-treated 303 
PC/BRAFV600E cells (Fig. 3B and C).  304 
In order to reinforce our observations, we further studied the activation of NF-κB signaling in response to 305 
the TLR4-agonist LPS in BCPAP cells harboring the BRAFV600E mutation. LPS stimulation of NF-κB reporter-306 
transiently transfected BCPAP cells showed a significant induction of NF-κB transcriptional activity (Fig. 3D). 307 
As mentioned, assay specificity was verified by inhibiting the activation of NF-κB signaling using BAY 11-308 
7082 (Fig. 3D). Additionally, we evidenced that BCPAP cells transiently expressing a non-signaling TLR4 309 
mutant missing the carboxy-terminus or a non-signaling MyD88—intracellular TLR4 signaling adaptor—310 
mutant missing the TLR4-interacting domain were not responsive to LPS stimulation (Fig. 3D). Consistently, 311 
LPS-induced TLR4-dependent signaling increased IL-6 and iNOS mRNA expression in BCPAP cells (Fig. 3E and 312 
F). Together, this evidence suggests that TLR4/MyD88/NF-κB signaling is functionally conserved in the PTC 313 
cell line BCPAP. 314 
 315 
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BRAFV600E-induced TLR4 gene expression involves MEK/ERK signal pathway. The oncogene BRAFV600E leads 316 
to constitutive activation of MAPK/ERK pathway by directly phosphorylating MEK, resulting in thyroid 317 
follicular cell transformation (23,34). To uncover the signal pathway involved in the regulation of TLR4 gene 318 
expression in response to BRAFV600E activity, we explored the effect of the specific BRAFV600E inhibitor 319 
PLX4032 and the MEK1/2 inhibitor U0126 on TLR4 expression in PC/BRAFV600E cells under doxycycline 320 
treatment. As expected, BRAFV600E inhibition reduced the upregulated TLR4 expression in response to 321 
doxycycline treatment (Fig. 4A). In line with the observed positive correlation between TLR4 expression and 322 
MAPK/ERK activation score, chemical inhibition of MAPK/ERK signaling activation reduced TLR4 expression 323 
in response to BRAFV600E induction (Fig. 4A). We analyzed ERK phosphorylation status by immunoblot to 324 
assess the inhibition of BRAFV600E-induced MAPK/ERK signaling in response to PLX4032 or U0126 treatment 325 
(Fig. 4A). Complementary, immunofluorescence performed under non-permeabilized conditions showed 326 
that chemical inhibition of MAPK/ERK signaling abrogated BRAFV600E-induced cell surface TLR4 protein 327 
expression levels (Fig. S5). Moreover, chemical inhibition of MAPK/ERK signaling activation reduced TLR4 328 
mRNA expression in response to BRAFV600E induction (Fig. 4B). To confirm this finding, we studied BRAFV600E-329 
regulated TLR4 gene expression in BCPAP cells. Interestingly, BCPAP cells treated with the chemical 330 
inhibitors PLX4032 or U0126 showed a significant reduction of TLR4 protein and mRNA expression levels 331 
(Fig. 4C and D). Altogether, these observations reinforce the involvement of MAPK/ERK signaling in the 332 
BRAFV600E-regulated TLR4 gene expression.  333 
 334 
A distal E26 transformation-specific (Ets)-binding site is crucial for TLR4 gene transcription in response to 335 
constitutive BRAFV600E signaling. To uncover the molecular mechanism involved in the BRAFV600E-induced 336 
TLR4 gene expression, we studied the transcriptional activity of sequential mouse TLR4 promoter deletions 337 
linked to luciferase in doxycycline-treated PC/BRAFV600E cells. The TLR4 promoter constructs -336/+223 and 338 
-608/+223 showed a significant transcriptional response to the induction of BRAFV600E expression (Fig. 5A). 339 
However, the promoter constructs +52/+223 and -104/+223 abrogated BRAFV600E-induced TLR4 340 
transcriptional activity (Fig. 5A). As reported, the sequence of the TLR4 promoter comprising nucleotides -341 
336 and -104 contains a distal Ets-binding site (Etsd) critical for constitutive TLR4 expression in mouse 342 
macrophages (24). Thereafter, we performed site-directed mutagenesis of the Etsd DNA-binding site within 343 
the −336/+223 promoter construct. Significantly, Etsd mutagenesis reduced BRAFV600E-induced TLR4 344 
promoter activity (Fig. 5B). Similar observations were done in PCCl3 cells conditionally expressing the 345 
oncogenes HRasG12V and RET/PTC3 (Fig. S6). 346 
In order to further test our observations, we constructed an artificial reporter containing three copies in 347 
tandem of the flanking region of the Etsd binding site linked to luciferase (3x Etsd-Luc). Significantly, 348 
BRAFV600E expression increased the luciferase activity of PC/BRAFV600E cells transiently transfected with the 349 
trimeric Etsd reporter construct (Fig. 5C). Moreover, we observed that the transcriptional activity of the 350 
−336/+223 TLR4 promoter construct missing the Etsd binding site (Etsd mt -336/+223) was significantly 351 
lower than that of the wild type promoter in BCPAP thyroid cancer cells (Fig. 5D). Together, these results 352 
support the involvement of the distal Ets-binding site in the transcriptional upregulation of TLR4 in 353 
response to BRAFV600E expression. 354 
 355 
The Ets-binding protein ETS1 mediates BRAFV600E-induced TLR4 gene expression. Ets-binding proteins 356 
(ETSs) are a family of transcription factors that share a conserved ~85 amino-acid sequence called Ets DNA-357 
binding domain (36). ETS transcription factors are involved in a wide variety of functions including 358 
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differentiation, proliferation, migration, apoptosis and angiogenesis. Significantly RAS/RAF signaling 359 
increases the transcriptional activity of some, but not all, ETS transcription factors through direct 360 
phosphorylation of MAPK/ERK signaling (36). 361 
To uncover the downstream BRAFV600E-induced ETS factors required for TLR4 gene overexpression, we used 362 
transcriptomic data derived from TCGA of PTC (33) to correlate the mRNA expression of TLR4 and different 363 
members of the ETS family in the subset of PTCs harboring the oncogene BRAFV600E. Interestingly, although 364 
a significant positive correlation with ELF1, ETV3 and GABPA, and negative correlation with ETV4 and ELK1 365 
were evidenced (Fig. S7A), the ETS ETS1 showed the highest positive association with TLR4 mRNA levels 366 
(r=0.5788, P<0.0001) (Fig. 6A), suggesting a potential role for ETS1 in the BRAFV600E-induced TLR4 gene 367 
overexpression in PTCs. In agreement, GEO dataset GSE33630 analysis also showed that the ETS family 368 
member ETS1 has the highest positive correlation with TLR4 mRNA expression in PTCs (Fig. S7B). 369 
Supporting these findings, ETS1 mRNA expression is up-regulated in PTCs harboring the oncogene BRAFV600E 370 
(37) and constitutes a critical genome-wide transcriptional effector of RAS/ERK signaling in tumor epithelial 371 
cells (32).  372 
We further explored ETS1 protein expression in tissue microarrays containing unmatched normal thyroid 373 
tissue (n=9) and PTCs (n=24) by immunohistochemistry. Although in the normal thyroid tissue ETS1 protein 374 
expression was detected at low levels, its expression was significantly upregulated in PTC (Fig. 6B). In tumor 375 
tissues, assessment of high-magnification images suggested that ETS1 was localized in both the cytoplasm 376 
and nucleus. Moreover, correlation analysis demonstrated a significant positive correlation between TLR4 377 
and ETS1 protein levels reinforcing a potential involvement of ETS1 transcriptional activity in TLR4 378 
expression levels (Fig. 6C). 379 
To elucidate the involvement of ETS1 as downstream target of BRAFV600E oncogenic activity, we studied 380 
ETS1 protein expression in response to doxycycline treatment in PC/BRAFV600E cells. Conditional BRAFV600E 381 
expression promoted an increase of ETS1 protein expression and its nuclear accumulation (Fig. 6D and E). In 382 
addition, we evidenced the involvement of MAPK/ERK signaling in the BRAFV600E-dependent ETS1 protein 383 
expression in PC/BRAFV600E and BCPAP cells (Fig. 6F and G). 384 
Moreover, in order to analyze the involvement of ETS1 in TLR4 gene expression, we studied BRAFV600E-385 
induced TLR4 mRNA expression in ETS1 knock-down PC/BRAFV600Ecells. Immunoblot analysis showed a 386 
successful knock-down of ETS1 protein levels in ETS1 siRNA transfected cells compared to scrambled (SCR) 387 
siRNA-transfected cells (Fig. 6H). Interestingly, we evidenced a significant inhibition of BRAFV600E-induced 388 
TLR4 mRNA expression levels in ETS1 knock-down cells compared to those of SCR siRNA-transfected cells 389 
(Fig. 6I). Consistently, analysis of TLR4 promoter activity showed that ETS1 knock-down repressed the 390 
BRAFV600E-increased TLR4 transcriptional activity (Fig. 6J). In agreement, TLR4 protein expression (Fig. 6K) 391 
and its promoter activity (Fig. 6L) showed a significant upregulation in PCCl3 normal thyroid cells transiently 392 
transfected to achieve ETS1 overexpression. 393 
Thereafter, we studied ETS1 binding to the TLR4 promoter in response to BRAFV600E expression in 394 
PC/BRAFV600E cells using ChIP assays. In detail, one putative Ets-binding site located between -240 and -233 395 
(relative to the transcription start site) in the rat TLR4 promoter was evidenced when its sequence was 396 
analyzed for putative Ets-binding sites using MatInspector software (Genomatix AG, Munich, Germany). 397 
Interestingly, ChIP assay with an anti-ETS1 antibody of doxycycline-treated PC/BRAFV600E cells revealed a 398 
significant enrichment in the TLR4 promoter sequence flanking the Ets-binding site (Fig. 6M). These data 399 
indicated that BRAFV600E-induced activation of MAPK/ERK signaling up-regulated directly ETS1 expression 400 
and binding to the TLR4 promoter that, in turn, modulated TLR4 gene expression. 401 
402 
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Accumulating evidence indicates the association between over-activation of TLRs signaling and cancer 404 
progression (1). Indeed, dysregulated TLRs signaling has been reported in several human cancers and 405 
related to an exacerbated production of a pro-inflammatory tumor microenvironment that provides the 406 
necessary context for tumor progression, angiogenesis, invasion, metastasis and evasion of immune 407 
surveillance (2). The biological relevance of TLRs expression in tumor cells seems complex, and the 408 
regulatory mechanisms leading to differential TLRs expression in cancer cells remains unclear.  409 
In the thyroid tissue, we demonstrated functional TLR4 expression in normal murine thyrocytes as TLR4 410 
engagement increased the expression of differentiation markers involved in thyroid hormonogenesis (16-411 
18). Here, in agreement with previous studies (19,20), we evidenced the presence of TLR4 protein 412 
overexpression in well-differentiated thyroid carcinoma compared to that of normal thyroid tissue. 413 
Moreover, we observed a significant up-regulation of TLR4 protein levels in lymph node metastasis derived 414 
from PTCs. Unfortunately, a limitation of our immunohistochemical study of thyroid tumor sections is the 415 
unavailability of information regarding the oncogenic driver promoting thyroid tumorigenesis. Therefore, 416 
we were unable to assess whether upregulated TLR4 protein expression is restricted to a particular 417 
oncogenic context. However, we did not evidence different TLR4 mRNA expression patterns among PTCs 418 
harboring different tumor driving oncogenes. Additionally, integrative analysis of clinical and transcriptomic 419 
data derived from TCGA of PTC (33) demonstrated that patients whose BRAFV600E-positive tumor showed 420 
high TLR4 expression, based on TLR4 expression above the median, had a lower median disease-free 421 
survival than those who showed TLR4 expression below the median. In close correlation, Dang et al. (20) 422 
demonstrated a higher incidence of lymph node and distant metastasis in patients with PTC showing high 423 
TLR4 expression levels. Mechanistically, these authors demonstrated that TLR4 engagement with low 424 
molecular weight hyaluronic acid induced a significant upregulation of CXCR7, the receptor of the 425 
chemokine CXCL12 involved in the promotion of tumor cell proliferation and migration (20). Although these 426 
findings support a potential pro-metastatic role for TLR4-mediated signaling in thyroid tumorigenesis, its 427 
participation in PTC aggressiveness and metastatic potential should be further evaluated. 428 
The ETSs regulate a plethora of processes, including differentiation, proliferation, apoptosis, and 429 
angiogenesis downstream MAPK/ERK signaling activation (36). Significantly, aberrant ETSs activation has 430 
been reported in several solid tumors (36). Particularly, the transcriptional activity of ETS1 and ETS2 is 431 
required for thyroid follicular cell transformation (38). Here, we provided novel evidence regarding the 432 
mechanisms that result in functional TLR4 overexpression in PTCs. Our data indicate that TLR4 gene 433 
overexpression in PTC is the consequence of dysregulated MAPK/ERK signaling due to thyroid cancer-driver 434 
oncogenes such as BRAFV600E. Roger et al. (24) carried out a detailed study of the mechanism controlling 435 
TLR4 gene expression regulation in mouse macrophages evidencing a distal Ets-binding site indispensable 436 
for constitutive TLR4 gene transcription which may be recognized by epithelium-specific ESE1 transcription 437 
factor. In this study, we demonstrated that the same Ets-binding site in the TLR4 promoter is critical for its 438 
transcriptional up-regulation in response to BRAFV600E oncogenic activity. Moreover, conducting 439 
bioinformatics analysis, and biochemical approaches, we revealed the direct role of ETS1 as transcriptional 440 
regulator of TLR4 gene expression downstream to BRAFV600E-induced MAPK-ERK signaling. In agreement, a 441 
comprehensive gene expression analysis of ETS1-regulated genes in PC3 prostate cancer cells 442 
demonstrated that ETS1 knock-down decreases TLR4 mRNA expression, suggesting that ETS1 constitutes a 443 
positive regulator of TLR4 gene expression in cancer cells (39). 444 
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Several studies indicate that single nucleotide polymorphisms in TLRs are associated with immune system 445 
dysregulated and cancer development (8). Polymorphisms in TLRs genes may shift the balance between 446 
pro- and anti-inflammatory cytokines, modulating the risk of infection, chronic inflammation, and cancer 447 
(8). Although TLR4 has been described as a highly polymorphic gene, certain TLR4 polymorphisms have 448 
been associated with a significant risk to develop epithelial cell-derived neoplasia. Particularly, the 449 
polymorphisms rs10116253 and rs1927911 in TLR4 gene were associated with decreased risk to develop 450 
gastric cancer (40), while the polymorphisms rs4986790, rs4986791 and rs10759932 appear to be positively 451 
associated with the development of gastric cancer (41). Moreover, the polymorphism rs11536889 located 452 
in the 3′-untranslated region of the TLR4 was associated with increased prostate and colon cancer risk 453 
(42,43). In thyroid carcinomas, however, the presence of TLR4 polymorphisms remains to be investigated. 454 
Significantly, Kim et al. (44) reported a case-control association study of the polymorphisms rs3804099 and 455 
rs3804100 in TLR2 gene in patients with PTC and control subjects, describing a significant association 456 
between polymorphisms in the TLR2 gene and bilateral thyroid tumors, a surgical criteria to perform total 457 
thyroidectomy. More recently, Kim et al. (45) reported a significant association of the missense 458 
polymorphism rs11466653 in TLR10 with a higher risk for the development of thyroid papillary 459 
microcarcinomas than in the control group. Together, these findings support that abnormal TLR signaling in 460 
PTC may be involved in the interplay between inflammation and tumorigenesis.  461 
TLRs recognize molecules that are broadly shared by pathogens but, sometimes, indistinguishable from 462 
host proteins released by stressed cells undergoing necrosis or proteolytic products derived from structural 463 
components of the extracellular matrix, collectively referred to as damage-associated molecular patterns 464 
(DAMPs). Here, we demonstrated that malignant thyroid follicular cells themselves are responsive to 465 
exogenous TLR4 agonists. However, the question regarding the endogenous molecules that engage TLR4 in 466 
the tumor environment to induce a signaling cascade leading to the NF-κB activation remains unanswered. 467 
We hypothesized that TLR4 signaling-activating DAMPs such as High mobility group box-1 (HMGB1) which is 468 
usually observed at high levels in the tumor microenvironment or hyaluronan-derived proteolytic products 469 
considering that hyaluronan is highly expressed in the tumor stroma of differentiated thyroid carcinomas 470 
(46) are likely candidates. Moreover, regarding the importance of DAMPs in thyroid tumor progression, 471 
recent evidence suggested that the multiligand receptor for advanced glycation end products (RAGE) 472 
mediates the pro-migratory response of extracellular small calcium-binding protein (S100A4) in human 473 
thyroid cancer cells (47). 474 
TLRs-triggered signal pathways culminate in the activation of the transcription factor NF-κB, which induces 475 
the expression of pro-inflammatory cytokines, anti-apoptotic factors, and pro-angiogenic factors (35). 476 
Recent evidence indicates that NF-κB signaling, as well as the pathways that culminate in its activation, are 477 
crucial players in many steps of carcinogenesis and tumor development (48). Genetic alterations leading to 478 
constitutive MAPK/ERK signaling have a fundamental role in thyroid carcinogenesis (34). However, 479 
additional molecular derangements are associated with tumor progression and aggressiveness. Particularly, 480 
aberrant NF-κB signaling activation is triggered by different oncogenes involved in thyroid carcinogenesis 481 
associated with a papillary phenotype (49) and linked to anaplastic thyroid tumorigenesis (21). NF-κB 482 
signaling activation has been associated with tumor progression, resistance to chemotherapeutic agents-483 
induced apoptosis and invasion associated with metalloproteinases expression (21). In close relation, the 484 
polymorphism rs2233406 in NFKBIA gene, an NF-κB signaling inhibitor, was associated with a pro-485 
inflammatory tumor microenvironment resulting from the exacerbated TLR4-dependent secretion of IL-1β 486 
that could favor tumor progression (50). 487 
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Overall, our findings raise an intriguing question regarding the pro-oncogenic potential of TLR4 downstream 488 
signaling in thyroid tumorigenesis, further considering that dysregulated NF-κB signaling has been 489 
implicated in thyroid cancer process (21). The understanding of TLR4 function in differentiated thyroid 490 
tumor development and growth as well as the mechanisms involved in these processes could have great 491 
clinical relevance. Further uncovering the mechanisms leading to TLR4 engagement and signaling in thyroid 492 
tumors may provide novel alternatives for the establishment of future therapies for thyroid cancer, and the 493 
design of new diagnostic procedures to identify a subset of potentially aggressive PTCs.  494 
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FIGURES AND FIGURE LEGENDS 638 
Figure 1. TLR4 is overexpressed in differentiated thyroid carcinomas. A. Representative normal and 639 
malignant thyroid sections showing TLR4 protein expression levels assessed by immunohistochemistry 640 
using a goat polyclonal anti-TLR4 antibody (sc-16240, Santa Cruz Biotechnology). Scale bar represents 641 
20 μm. Quantification of TLR4 protein levels was expressed relative to the number of cells in the tissue 642 
sections and plotted as median with interquartile range. *** P<0.001 vs. normal tissue (Kruskal-Wallis test, 643 
Dunn's test). B and C. TLR4 protein expression in match-samples of tumor adjacent normal thyroid tissue 644 
and PTC, and match-samples of primary PTC and its lymph node metastasis. Scale bar represents 20 μm. * 645 
P<0.05 (Paired t test). D. Analysis of TLR4 mRNA expression as a function of the most frequent driver 646 
oncogenes identified in PTCs, including point mutations of BRAF (n=234), HRAS (n=14), and NRAS (n=34) 647 
genes, as well as fusions involving NTRK (n=10) and RET (n=32) tyrosine kinases, and BRAF (n=12) kinase. E. 648 
Correlative analysis showing TLR4 mRNA expression and ERK activation score in PTCs harboring oncogenes 649 
classically involved in MAPK/ERK signaling activation (n=336, Spearman’s correlation test). ERK score was 650 
calculated based on a 52-gene signature to assess the MAPK/ERK signaling pathway activation (33). F. 651 
Correlative analysis showing TLR4 mRNA expression and thyroid differentiation score in PTCs harboring the 652 
oncogene BRAFV600E (n=234, Spearman’s correlation test). Thyroid differentiation score was calculated 653 
based on a 16-gene signature related to thyroid metabolism and function (33). G. Correlative analysis 654 
showing TLR4 mRNA expression and MACIS score in PTCs harboring the oncogene BRAFV600E (n=212, 655 
Spearman’s correlation test). H. Disease-free survival analysis of patients whose thyroid tumors harbored 656 
the oncogene BRAFV600E (wild-type TERT status) and expressed low (n=97) or high (n=88) TLR4 mRNA levels, 657 
based on its expression below and above the median within the group. P=0.0071 (Mantel-Cox test).  658 
Figure 2. Conditional oncogene expression induced TLR4 expression in PTC models. A. RT/qPCR assessing 659 
TLR4 mRNA expression levels in response to doxycycline (Dox)-induced BRAFV600E, HRasG12V, or RET/PTC3 660 
expression at 48 h in PCCl3 cells. * P<0.05 and ** P<0.01 vs. vehicle-treated cells (one-way ANOVA, 661 
Newman-Keuls test). B and C. Immunoblot assessing TLR4 protein expression levels in response to 662 
conditional BRAFV600E expression for 48 h in PC/BRAF cells (B) or transient transfection of BRAFV600E into 663 
non-tumoral Nthy-ori 3-1 thyroid cells (C). Fold change indicates relative TLR4 abundance. * P<0.05 vs. 664 
vehicle-treated cells or empty vector-transfected cells (unpaired Student’s t test). D. Immunofluorescence 665 
under non-permeabilized conditions analyzing TLR4 protein expression at the plasma membrane in 666 
response to BRAFV600E expression for 48 h in PC/BRAF cells. Scale bar represents 10 μm. *** P<0.001 vs. 667 
vehicle-treated cells (unpaired Student’s t test). E and F. Analysis of TLR4 mRNA and protein expression in 668 
the thyroid tissue of transgenic mice conditionally expressing BRAFV600E in the thyroid follicular cell and 669 
littermate control mice. Scale bar represents 20 μm. Quantification of TLR4 protein expression was 670 
expressed relative to the numbers of cells in the tissue sections. * P<0.05 and ** P<0.001 (Mann Whitney t 671 
test). 672 
Figure 3. TLR4 signaling in PTC cell models. A. NF-κB reporter activity in doxycycline (Dox)-treated 673 
PC/BRAFV600E cells stimulated with the exogenous TLR4-agonist LPS. The NF-κB inhibitor BAY 11-7082 is 674 
used as specificity control. *** P<0.001 vs. vehicle-treated cells, # P<0.05 vs. Dox-treated cells in the 675 
absence of LPS, ƗƗ P<0.01 and ƗƗƗ P<0.001 vs. Dox-treated cells (one-way ANOVA, Newman-Keuls test). B and 676 
C. RT/qPCR assessing the mRNA expression of the NF-κB targets IL-6 and iNOS in response to TLR4 677 
activation for 12 h. ** P<0.01 and *** P<0.001 vs. vehicle-treated cells, ### P<0.001 vs. LPS-treated cells 678 
(one-way ANOVA, Newman-Keuls test). D. NF-κB reporter activity in empty or non-signaling TLR4 or MyD88 679 
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vectors-transfected BCPAP cells stimulated with LPS for 24 hs. Empty vector-transfected cells treated with 680 
BAY 11-7082 serves as specificity control. ** P<0.01 vs. vehicle-treated cells, ## P<0.01 and ### P<0.001 vs. 681 
LPS-treated empty vector-transfected cells (one-way ANOVA, Newman-Keuls test). E and F. RT/qPCR 682 
assessing the mRNA expression of IL-6 and iNOS in BCPAP cells stimulated with LPS for 12 hs. *** P<0.001 683 
vs. vehicle-treated cells, ### P<0.001 vs. LPS-treated cells (one-way ANOVA, Newman-Keuls test).  684 
Figure 4. MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E. A and B. TLR4 685 
protein and mRNA expression in doxycycline-treated PC/BRAFV600E cells in the presence of the chemical 686 
inhibitors PLX4032 or U0126. Fold change indicates relative TLR4 abundance. * P<0.05 and ** P<0.01 vs. 687 
vehicle-treated cells, # P<0.05 vs. same condition in absence of inhibitor (one-way ANOVA, Newman-Keuls 688 
test). C and D. TLR4 protein and mRNA expression in BCPAP cells treated in the presence of the chemical 689 
inhibitors PLX4032 or U0126. Fold change indicates relative TLR4 abundance. * P<0.05 and ** P<0.01 vs. 690 
vehicle-treated cells (one-way ANOVA, Newman-Keuls test). 691 
Figure 5. Etsd binding site is crucial for TLR4 gene transcription in response to constitutive BRAFV600E 692 
signaling. A. Transcriptional activity of TLR4 promoter deletion constructs in response to BRAFV600E 693 
expression in PC/BRAFV600E cells. * P<0.05 and *** P<0.001 vs. vehicle-treated cells (unpaired Student’s t 694 
test). B. Transcriptional activity of the Etsd binding-site mutated TLR4 promoter construct -336/+223 in 695 
PC/BRAFV600E cells. *** P<0.001 vs. vehicle-treated cells, ### P<0.001 vs. -336/+223-transfected cells (one-696 
way ANOVA, Newman-Keuls test). C. Transcriptional activity of the trimeric Etsd reporter construct 3x Etsd-697 
Luc in PC/BRAFV600E cells in response to doxycycline (Dox) treatment. * P<0.05 (unpaired Student’s t test). D. 698 
Transcriptional activity of the TLR4 promoter construct -336/+223 and Etsd binding-site mutated TLR4 699 
promoter construct -336/+223 in BCPAP cells. ** P<0.01 vs. -336/+223-transfected cells (unpaired Student’s 700 
t test). 701 
Figure 6. ETS1 mediates BRAFV600E-induced TLR4 gene expression. A. Correlation analysis of TLR4 mRNA 702 
expression as a function of ETS1 mRNA expression in the subset of PTC harboring the oncogene BRAFV600E 703 
(n=234, Spearman’s correlation test). B. Representative unmatched sections of normal thyroid tissue and 704 
PTC showing ETS1 protein expression levels assessed by immunohistochemistry using a rabbit polyclonal 705 
anti-ETS1 antibody (sc-350, Santa Cruz Biotechnology). Scale bar represents 20 μm. Quantification of ETS1 706 
protein levels was expressed relative to the number of cells in the tissue sections and plotted as median 707 
with interquartile range. *** P<0.001 vs. normal tissue (Mann Whitney test). C. Correlation analysis of TLR4 708 
and ETS1 protein expression assessed by immunohistochemistry in equivalent PTC tissues (n=24, 709 
Spearman’s correlation test). D. Immunoblot analysis assessing nuclear ETS1 protein levels in response to 710 
BRAFV600E expression in PC/BRAFV600E cells. PARP-1 and α-Tubulin were used as nuclear and cytoplasmic 711 
loading markers, respectively. Fold change indicates relative ETS1 abundance. * P<0.05 (unpaired Student’s 712 
t test). E. Immunofluorescence analysis under permeabilized conditions showing ETS1 protein expression in 713 
response to doxycycline (Dox) treatment in PC/BRAFV600E cells. Scale bar represents 10 μm. * P<0.05 714 
(unpaired Student’s t test). F and G. MAPK/ERK-dependent ETS1 protein expression in response to 715 
BRAFV600E oncogenic activity in PC/BRAFV600E and BCPAP cells. Fold change indicates relative ETS1 716 
abundance. * P<0.05 vs. vehicle-treated cells (one-way ANOVA, Newman-Keuls test). H. Immunoblot 717 
analysis showing ETS1 protein expression in scramble (SCR) or ETS1 siRNA transfected PC/BRAFV600E cells. 718 
Fold change indicates relative ETS1 abundance. * P<0.05 (unpaired Student’s t test). I. TLR4 mRNA 719 
expression in doxycycline (Dox)-treated scramble (SCR) or ETS1 siRNA-transfected PC/BRAFV600E cells. ** 720 
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P<0.01 vs. vehicle-treated cells, ## P<0.01 vs siSCR-transfected cells (one-way ANOVA, Newman-Keuls test). 721 
J. Transcriptional activity of the TLR4 promoter construct -336/+223 in doxycycline (Dox)-treated scramble 722 
(SCR) or ETS1 siRNA-transfected PC/BRAFV600E cells. * P<0.05 (one-way ANOVA, Newman-Keuls test). K. 723 
Immunoblot analysis showing TLR4 protein expression in empty or ETS1 expressing vector-transfected 724 
normal PCCl3 cells. Fold change indicates relative TLR4 abundance. * P<0.05 (unpaired Student’s t test). L. 725 
Transcriptional activity of the TLR4 promoter construct -336/+223 in empty or ETS1 expressing vector-726 
transfected normal PCCl3 cells. ** P<0.01 (unpaired Student’s t test). M. ChIP analysis assessing ETS1 727 
binding to TLR4 promoter region -365 to -24 (relative to the transcription start site) in response to BRAFV600E 728 
induction in PC/BRAFV600E cells. ** P<0.01 vs. vehicle-treated cells (unpaired Student’s t test). 729 
on March 11, 2018. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 9, 2018; DOI: 10.1158/1541-7786.MCR-17-0433 
on March 11, 2018. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 9, 2018; DOI: 10.1158/1541-7786.MCR-17-0433 
on March 11, 2018. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 9, 2018; DOI: 10.1158/1541-7786.MCR-17-0433 
on March 11, 2018. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 9, 2018; DOI: 10.1158/1541-7786.MCR-17-0433 
on March 11, 2018. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 9, 2018; DOI: 10.1158/1541-7786.MCR-17-0433 
on March 11, 2018. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 9, 2018; DOI: 10.1158/1541-7786.MCR-17-0433 
on March 11, 2018. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 9, 2018; DOI: 10.1158/1541-7786.MCR-17-0433 
 Published OnlineFirst March 9, 2018.Mol Cancer Res 
  
Victoria Peyret, Magalí Nazar, Mariano Martin, et al. 
  
Activity
Thyroid Cancer by MAPK/ERK-induced ETS1 Transcriptional 



































Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://mcr.aacrjournals.org/content/early/2018/03/09/1541-7786.MCR-17-0433
To request permission to re-use all or part of this article, use this link
on March 11, 2018. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 9, 2018; DOI: 10.1158/1541-7786.MCR-17-0433 
